Definium Therapeutics reported late-stage progress for DT-120 (lysergide) in generalized anxiety disorder, clearing the bar in the first of two Phase III trials. The update follows recent Phase III success in major depressive disorder, keeping the psychedelic program on an accelerated development path. In early clinical development, Zealand Pharma sold rights tied to Takeda’s rusfertide ahead of a forthcoming FDA decision for the blood-cancer asset. The $100 million transaction underscores how regulatory timing is increasingly leveraged to de-risk pipeline bets. In oncology diagnostics, Natera and Kupando initiated a Phase I skin cancer trial in Germany that uses Natera’s Latitude ctDNA assay to track molecular residual disease and treatment response dynamics across time points.